Acquisitions - Additional Information (Details)		1 Months Ended			12 Months Ended
	Jul. 01, 2021 USD ($)	Feb. 28, 2021 USD ($) Milestone	Aug. 31, 2017 USD ($) shares	Sep. 30, 2016 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($) Milestone	Feb. 28, 2022 USD ($)	Jan. 31, 2022 USD ($)	Jul. 31, 2021 shares
TomegaVax
Business Acquisition [Line Items]
Asset acquisition purchase price				$ 5,200,000
Asset acquisition, transaction costs				$ 500,000
Payment made for asset acquisition milestone	$ 8,100,000
Common stock shares Issued for milestone payment| shares | shares									42,737
Value of common stock shares Issued for milestone payment	1,900,000
Minimum common stock price for milestone payments consideration | $ / shares				$ 90
TomegaVax | Maximum
Business Acquisition [Line Items]
Remaining payment for asset acquisition milestone, maximum	$ 20,000,000.0
TomegaVax | Clinical Development
Business Acquisition [Line Items]
Minimum common stock price for milestone payments consideration | $ / shares				$ 45
TomegaVax | TomegaVax Letter Agreement
Business Acquisition [Line Items]
Milestone payments aggregate amount payable, maximum				$ 30,000,000.0
Milestone payments related terms					the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company’s publicly traded common stock, or implied price per-share of the Company’s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company’s clinical development at the time of the relevant event triggering the payment.
Estimated fair value of embedded derivative					$ 5,700,000
Contingent consideration recognized		$ 10,000,000.0
Number of milestones achieved | Milestone		1
Minimum common stock price for milestone payments consideration | $ / shares				$ 45
Humabs
Business Acquisition [Line Items]
Contingent consideration recognized					17,100,000	$ 29,200,000
Business acquisition, cash consideration paid			$ 30,000,000.0
Business acquisition, shares issued | shares			1,666,656
Business acquisition, shares issued value			$ 2,500,000
Sales milestone achieved					60,000,000.0
Impairment of intangible assets, excluding goodwill					0
Goodwill expected to be deductible for income tax purposes					$ 0
Humabs | Developed Technologies | Minimum [Member]
Business Acquisition [Line Items]
Estimated remaining useful lives					7 years
Humabs | Developed Technologies | Maximum
Business Acquisition [Line Items]
Estimated remaining useful lives					12 years
Humabs | HBV product
Business Acquisition [Line Items]
Additional consideration payable upon achievement of specified milestone events			135,000,000.0
Specified clinical development milestones payment						$ 20,000,000.0
Humabs | Another Product
Business Acquisition [Line Items]
Additional consideration payable upon achievement of specified milestone events			$ 105,000,000.0
Humabs | SARS-CoV-2 Product
Business Acquisition [Line Items]
Contingent consideration recognized					$ 17,100,000
Number of specified clinical milestones achieved | Milestone						2
Specified clinical development milestones payment						$ 20,000,000.0
Regulatory milestones achieved					35,000,000.0
Sales milestone achieved					$ 60,000,000.0
Humabs | SARS-CoV-2 Product | Subsequent Event
Business Acquisition [Line Items]
Payment made for business combination milestone							$ 60,000,000.0	$ 35,000,000.0